Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis & rheumatology (Hoboken, N.J.) Genovese, M. C., Greenwald, M., Codding, C., Zubrzycka-Sienkiewicz, A., Kivitz, A. J., Wang, A., Shay, K., Wang, X., Garg, J. P., Cardiel, M. H. 2017

Abstract

To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA).In this randomized, double-blind, phase IIb trial, patients with RA (n?=?289) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg or matching placebo once daily for 12 weeks. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at week 12.ACR20 response rates at week 12 were 22.0%, 36.8%, 48.3% (P?

View details for DOI 10.1002/art.40054

View details for PubMedID 28118538